Lisinopril vs Ramipril

Both lisinopril and ramipril effectively lower blood pressure by 10–15 mmHg systolic with typical doses ^[1]. Ramipril gained its reputation from the HOPE trial (Heart Outcomes Prevention Evaluation), which showed a 22% reduction in the combined endpoint of cardiovascular death, myocardial infarction, and stroke in high-risk patients, independent of blood pressure effects ^[2]. Lisinopril demonstrated mortality reduction in heart failure in the ATLAS trial (high-dose vs low-dose) and post-MI benefit in GISSI-3 ^[3]. For diabetic nephropathy, both provide renal protection by reducing proteinuria, but ramipril has specific evidence from the MICRO-HOPE substudy showing reduction in overt nephropathy ^[2]. A 2015 meta-analysis found no significant difference between individual ACE inhibitors for blood pressure reduction when used at equivalent doses ^[4]. Ramipril's cardiovascular protection evidence is often considered the strongest in the ACE inhibitor class.

Both medications share the characteristic ACE inhibitor side-effect profile. Dry cough is the most common class effect, occurring in 5–20% of patients and resulting from bradykinin accumulation ^[1]. There is no consistent evidence that one ACE inhibitor causes more cough than another. Angioedema is a rare (0.1–0.7%) but potentially serious adverse effect of all ACE inhibitors ^[3]. Hyperkalemia occurs in 1–3% of patients, particularly those with renal impairment or taking potassium supplements. First-dose hypotension is possible with both drugs, though ramipril's prodrug design provides a more gradual onset that may reduce this risk ^[2]. Dizziness (3–5%), headache (3–5%), and fatigue are common. Both drugs are contraindicated in pregnancy. Ramipril is primarily hepatically metabolized, while lisinopril is renally eliminated unchanged, which means lisinopril requires dose adjustment in renal impairment while ramipril may need adjustment in severe hepatic dysfunction ^[4].

Both drugs are available as inexpensive generics. Generic lisinopril 10 mg (30 tablets) costs $3–8 at most pharmacies, making it one of the cheapest prescription medications available ^[1]. Generic ramipril 5 mg (30 capsules) costs $8–20, slightly more than lisinopril but still very affordable. Brand-name Zestril and Altace cost $100–200/month but are rarely used. Both are on most pharmacy $4 generic lists. Insurance coverage is universal for both medications at the lowest copay tier.

Both are taken once daily, typically in the morning. Lisinopril is available in 2.5, 5, 10, 20, 30, and 40 mg tablets with a dose range of 10–40 mg/day ^[1]. Ramipril comes in 1.25, 2.5, 5, and 10 mg capsules with a range of 2.5–20 mg/day ^[2]. Neither requires administration with food, though ramipril capsules can be opened and sprinkled on applesauce for patients with swallowing difficulty. Lisinopril's broader range of tablet strengths allows finer dose titration. As the only non-prodrug ACE inhibitor, lisinopril has a more predictable dose-response relationship, which can simplify titration ^[3]. Neither drug requires routine laboratory monitoring beyond periodic renal function and potassium checks.

Lisinopril is a practical first choice for most patients needing an ACE inhibitor due to its lower cost, wide availability, multiple tablet strengths for easy titration, and predictable pharmacokinetics as a non-prodrug ^[1]. Ramipril may be preferred for patients at high cardiovascular risk without heart failure (based on HOPE trial evidence), patients with diabetes and microalbuminuria (MICRO-HOPE evidence), or patients with hepatic impairment (lisinopril may be better here as it is renally eliminated) ^[2][4]. For patients with significant renal impairment, ramipril's hepatic metabolism may offer an advantage, though dose adjustment is still needed for severe cases. Both are excellent, well-studied ACE inhibitors. Consult your healthcare provider to choose the best option for your risk profile.